Skip to content
Bored Studies
RecruitingPhase 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Incyte Corporation · NCT06855498

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
600
US sites recruiting
74
Study start
February 28, 2025
Record last updated
October 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Being studied: povorcitinib

Conditions: Hidradenitis Suppurativa (HS)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
  • Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
  • Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
  • Willingness to avoid pregnancy or fathering children as defined in the protocol.
  • Willingness and ability to comply with the study Protocol and procedures.

Exclusion Criteria

  • Had been permanently discontinued from study treatment during the parent study.
  • Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
  • Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
  • Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
  • Live, attenuated vaccine.
  • Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
  • Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Recruiting US locations

+ 14 more on the official record.

Study contacts (from the official record)

  • Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
  • Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
All dermatology studies in Alabama →
Rollover Study for Participants Previously Enrolled in Clinical… (NCT06855498) | Bored Studies